Partner Gabor Garai was quoted in an article that appeared in the Boston Globe on May 10, 2013 titled, “Markets draw life science start-ups.” The article discussed how rebounding financial markets are attracting an increasing number of life sciences start-ups looking to raise large amounts of money through IPOs — resulting in the anticipated biggest coming-out class for life sciences since 2007. The article highlighted the risks to going public, but noted that public offerings are emerging as the financing event of choice for start-ups that do not want to give up too much control to private investors or larger industry players. Mr. Garai was quoted as saying, “When it comes to drugs, the cost of getting anything to market has become inordinate. Right now, there’s more money in the public markets chasing deals than in the venture capital markets. We’re seeing the first signs of spring after a cold winter for IPOs.”
People
Related News
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."
August 5, 2025
In the News
Aaron Maguregui on Health Data Sharing Plan – 'I would expect the FTC to be heavily involved'
Foley & Lardner LLP partner Aaron Maguregui addressed a new health care data sharing initiative announced by the federal government in the Bloomberg Law article, "Digital Data-Sharing Plan Tests Limits of Health Privacy Rules."